Recent News

• 09.04.2025 - Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
• 08.19.2025 - Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
• 08.13.2025 - Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
• 07.31.2025 - Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
• 07.16.2025 - Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
• 06.24.2025 - Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
• 06.11.2025 - Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
• 06.04.2025 - Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
• 05.13.2025 - Ensysce Biosciences Reports First Quarter 2025 Financial Results
• 05.12.2025 - Ensysce Biosciences Bolsters Management Team with Regulatory Expert

Recent Filings

• 08.13.2025 - 8-K Current report
• 08.13.2025 - EX-99.1 EX-99.1
• 08.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.12.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 06.05.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors